|Dr. Jon Anthony Joseph Burrows B.Sc., M.Sc., Ph.D.||CEO & Director||463k||N/A||1963|
|Mr. Paul Leslie Stockdale F.C.A., M.A.||CFO & Director||202k||N/A||1975|
|Dr. Alexandre Akoulitchev Ma (Oxon), Ph.D.||Chief Scientific Officer & Director||236k||N/A||1962|
|Mr. Thomas G. Guiel B.A.||Chief Operating Officer||N/A||N/A||N/A|
|Dr. Jayne Green B.Sc., Ph.D.||Director of Operations||N/A||N/A||N/A|
|Dr. Ewan Hunter B.Sc., BSC, Ph.D., Ph.D., (KCL)||C.D.O||N/A||N/A||N/A|
|T. Demain||Company Sec.||N/A||N/A||N/A|
|Dr. Steven Tucker M.D., FACP||Group Clinical Director||N/A||N/A||N/A|
|Prof. Siamon Gordon||Clinical Director of Inflammation & Infection||N/A||N/A||N/A|
|Dr. Sandy Primrose Ph.D.||Technical Consultant||N/A||N/A||N/A|
Oxford BioDynamics Plc, a biotechnology company, discovers and develops biomarkers for use in the pharmaceutical and biotechnology industry primarily in the United States and internationally. The company provides EpiSwitch, a proprietary technology platform for the discovery, evaluation, validation, and monitoring of epigenetic biomarkers known as chromosome conformation signatures for use in medical testing kits, disease prediction, diagnosis, and treatment. Its products include EpiSwitch CiRT (Checkpoint Inhibitor Response Test), a validated prognostic test for predicting response to checkpoint inhibitor immunotherapy; EpiSwitch CST (Covid Severity Test), an advanced blood test for the prediction of COVID-19 severity in adults; and EpiSwitch Explorer Array Kit for high-resolution 3D genome profiling and biomarker discovery. Oxford BioDynamics Plc was incorporated in 2007 and is headquartered in Oxford, the United Kingdom.
Oxford BioDynamics Plc’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.